
Noémie Jourde-Chiche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2067067/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>Bartonella and Coxiella</i> infections presenting as systemic vasculitis: case series and review of literature. Rheumatology, 2022, 61, 2609-2618.	1.9	15
2	Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement. Clinical Rheumatology, 2022, 41, 1483-1491.	2.2	6
3	Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. Journal of the American Society of Nephrology: JASN, 2022, 33, 628-637.	6.1	24
4	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. Presse Medicale, 2022, 51, 104107.	1.9	2
5	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. BMC Nephrology, 2022, 23, 67.	1.8	3
6	RÃ1e du complément dans la néphropathie lupique et la néphropathie du syndrome des anti-phospholipides. La Presse Médicale Formation, 2022, 3, 156-156.	0.1	0
7	Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. CKJ: Clinical Kidney Journal, 2022, 15, 1747-1754.	2.9	10
8	Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Kidney International, 2022, 102, 904-916.	5.2	12
9	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 1420-1427.	0.9	24
10	Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. Scientific Reports, 2022, 12, .	3.3	2
11	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA Network Open, 2022, 5, e2220925.	5.9	18
12	Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrology Dialysis Transplantation, 2021, 36, 1664-1674.	0.7	41
13	Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al. Arthritis and Rheumatology, 2021, 73, 717-718.	5.6	3
14	lgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients. Journal of Rheumatology, 2021, 48, 735-740.	2.0	7
15	Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology, 2021, 60, 4245-4251.	1.9	9
16	Diagnostic performance of pulmonary ultrasonography and a clinical score for the evaluation of fluid overload in haemodialysis patients. Nephrologie Et Therapeutique, 2021, 17, 42-49.	0.5	3
17	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. Kidney International Reports, 2021, 6, 746-754.	0.8	8
18	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Seminars in Arthritis and Rheumatism, 2021, 51, 339-346.	3.4	22

Noémie Jourde-Chiche

#	Article	IF	CITATIONS
19	Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. Hypertension, 2021, 77, 1260-1272.	2.7	2
20	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine, 2021, 10, 1690.	2.4	10
21	Unsupervised clustering analysis of data from an online community to identify lupus patient profiles with regards to treatment preferences. Lupus, 2021, 30, 1837-1843.	1.6	8
22	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
23	Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2239-2245.	2.9	12
24	Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys. Kidney International Reports, 2021, 6, 2134-2143.	0.8	4
25	Kidney biopsy in very elderly patients: indications, therapeutic impact and complications. BMC Nephrology, 2021, 22, 362.	1.8	2
26	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1665-1675.	4.5	8
27	Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus. Rheumatology, 2020, 59, 1975-1983.	1.9	10
28	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. Arthritis Research and Therapy, 2020, 22, 223.	3.5	18
29	Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. BMC Nephrology, 2020, 21, 260.	1.8	10
30	Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. CKJ: Clinical Kidney Journal, 2020, 13, 878-888.	2.9	43
31	Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis. Kidney International, 2020, 97, 1102-1104.	5.2	12
32	P0360URINARY PEPTIDOMIC ANALYSIS IN PROLIFERATIVE VERSUS NON-PROLIFERATIVE LUPUS NEPHRITIS : RESULTS OF THE PEPTIDU-LUP STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
33	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology, 2020, 59, 2970-2975.	1.9	7
34	Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. Rheumatology, 2020, 59, 3050-3057.	1.9	23
35	First phenotypic description of a female patient with c.610 T > C variant of GLA: a renal-predominant presentation of Fabry disease. BMC Medical Genetics, 2020, 21, 137.	2.1	1
36	Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium. Kidney International Reports, 2020, 5, 1071-1075.	0.8	2

#	Article	IF	CITATIONS
37	Serum GlycA Level Is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. Journal of Clinical Medicine, 2020, 9, 970.	2.4	8
38	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 964-972.	4.5	13
39	Endothelial Toxicity of High Clucose and its by-Products in Diabetic Kidney Disease. Toxins, 2019, 11, 578.	3.4	32
40	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	5.2	74
41	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. Journal of Clinical Medicine, 2019, 8, 298.	2.4	3
42	MYH9-related disorders display heterogeneous kidney involvement and outcome. CKJ: Clinical Kidney Journal, 2019, 12, 494-502.	2.9	16
43	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney International, 2019, 95, 666-679.	5.2	68
44	Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	27
45	Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108.	9.6	292
46	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology, 2019, 85, 403-412.	2.4	39
47	Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Archives of Toxicology, 2019, 93, 121-136.	4.2	43
48	Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. Kidney International, 2018, 93, 986-999.	5.2	79
49	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases, 2018, 77, 1143-1149.	0.9	219
50	Apheresis to treat systemic vasculitis. Joint Bone Spine, 2018, 85, 177-183.	1.6	12
51	Autoantibodies Targeting Ficolinâ€⊋ in Systemic Lupus Erythematosus Patients With Active Nephritis. Arthritis Care and Research, 2018, 70, 1263-1268.	3.4	14
52	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	5.8	62
53	Hemodialysis vascular graft as a focus of persistent Q fever. Infection, 2018, 46, 881-884.	4.7	8
54	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	4.8	42

#	Article	IF	CITATIONS
55	Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling. Journal of the American Society of Nephrology: JASN, 2018, 29, 906-918.	6.1	21
56	Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology, 2017, 56, kew439.	1.9	34
57	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
58	Aphérèses dans le traitement des vascularites systémiques. Revue Du Rhumatisme Monographies, 2017, 84, 270-275.	0.0	1
59	Characteristics and Management of IgA Vasculitis (Henochâ€5chönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis and Rheumatology, 2017, 69, 1862-1870.	5.6	117
60	Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection. Case Reports in Transplantation, 2017, 2017, 1-7.	0.3	8
61	From BLISS to ILLUMINATE studies: "Blys repetita placentâ€?: TableÂ1. Annals of the Rheumatic Diseases, 2016, 75, e10-e10.	0.9	2
62	Introducing a New Dimension to Molecular Disease Classifications. Trends in Molecular Medicine, 2016, 22, 451-453.	6.7	7
63	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (United States), 2016, 95, e3748.	1.0	64
64	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 431-441.	4.5	54
65	Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: Results of a multiple cause-of-death analysis in France. Seminars in Arthritis and Rheumatism, 2016, 46, e6-e7.	3.4	3
66	An interactive web application for the dissemination of human systems immunology data. Journal of Translational Medicine, 2015, 13, 196.	4.4	49
67	The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. Journal of the American Society of Nephrology: JASN, 2015, 26, 876-887.	6.1	239
68	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. Journal of Autoimmunity, 2015, 65, 49-55.	6.5	34
69	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty‧even Patients. Arthritis and Rheumatology, 2015, 67, 527-534.	5.6	136
70	Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures. Arthritis and Rheumatology, 2014, 66, 1583-1595.	5.6	302
71	Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multiple auseâ€ofâ€Đeath Analysis. Arthritis and Rheumatology, 2014, 66, 2503-2511.	5.6	152
72	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney International, 2013, 84, 733-744.	5.2	205

#	Article	IF	CITATIONS
73	Disease Mechanisms in Rheumatology—Tools and Pathways: Current Perspectives on Systems Immunology Approaches to Rheumatic Diseases. Arthritis and Rheumatism, 2013, 65, 1407-1417.	6.7	21
74	Original Approach for Automated Quantification of Antinuclear Autoantibodies by Indirect Immunofluorescence. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	20
75	Association between anti-C1q antibodies and glomerular tuft necrosis in lupus nephritis. Clinical Nephrology, 2012, 77, 211-218.	0.7	11
76	Vascular Incompetence in Dialysis Patients—Proteinâ€Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis, 2011, 24, 327-337.	1.3	158
77	Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2281-2286.	2.3	63
78	Does Uremia Cause Vascular Dysfunction. Kidney and Blood Pressure Research, 2011, 34, 284-290.	2.0	122
79	PROGRESS IN UREMIC TOXIN RESEARCH: Proteinâ€Bound Toxins—Update 2009. Seminars in Dialysis, 2009, 22, 334-339.	1.3	139
80	Reply to â€~Kidney involvement in hereditary transthyretin amyloidosis: is there a role for cystatin C?'. CKJ: Clinical Kidney Journal, 0, , .	2.9	1